These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31237430)

  • 1. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
    Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N
    Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
    Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
    Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.
    Guimbellot J; Solomon GM; Baines A; Heltshe SL; VanDalfsen J; Joseloff E; Sagel SD; Rowe SM;
    J Cyst Fibros; 2019 Jan; 18(1):102-109. PubMed ID: 29685811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
    Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation.
    McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E
    J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
    De Boeck K; Munck A; Walker S; Faro A; Hiatt P; Gilmartin G; Higgins M
    J Cyst Fibros; 2014 Dec; 13(6):674-80. PubMed ID: 25266159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function.
    Salvatore D; Terlizzi V; Francalanci M; Taccetti G; Messore B; Biglia C; Pisi G; Calderazzo MA; Caloiero M; Pizzamiglio G; Majo F; Cresta F; Leonetti G; De Venuto D
    Respir Med; 2020 Sep; 171():106073. PubMed ID: 32846335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
    Guimbellot JS; Baines A; Paynter A; Heltshe SL; VanDalfsen J; Jain M; Rowe SM; Sagel SD;
    J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic fibrosis with non-G551D gating mutations in Italy: Epidemiology and clinical characteristics.
    Salvatore D; Carnovale V; Majo F; Padoan R; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
    Pediatr Pulmonol; 2021 Feb; 56(2):442-449. PubMed ID: 33219628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
    Dagan A; Cohen-Cymberknoh M; Shteinberg M; Levine H; Vilozni D; Bezalel Y; Bar Aluma BE; Sarouk I; Ashkenazi M; Lavie M; Tsabari R; Blau H; Kerem E; Bentur L; Efrati O; Livnat G
    Respir Med; 2017 Oct; 131():225-228. PubMed ID: 28947035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
    McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
    Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
    Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
    Rosenfeld M; Wainwright CE; Higgins M; Wang LT; McKee C; Campbell D; Tian S; Schneider J; Cunningham S; Davies JC;
    Lancet Respir Med; 2018 Jul; 6(7):545-553. PubMed ID: 29886024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
    Trimble AT; Donaldson SH
    J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.